Share on LinkedInShare on LinkedIn

ARTICLE · 02 JANUARY 2024

EYLEA® (Aflibercept) And Soliris® (Eculizumab) IPR Updates

On December 8, 2023, the PTAB instituted three of Samsung Bioepis's pending IPRs against Alexion's Soliris® (eculizumab), IPR2023-00933, IPR2023-00998, and IPR2023-00999.

United StatesIntellectual Property

Soliris® (eculizumab)

On December 8, 2023, the PTAB instituted three of Samsung Bioepis's pending IPRs against Alexion's Soliris® (eculizumab), IPR2023-00933, IPR2023-00998, and IPR2023-00999. The challenged patents include composition of matter, formulation, and method of treatment claims. Samsung Bioepis filed two additional IPRs in June, IPR2023-01069 and IPR2023-01070, that are awaiting institution decisions. While Samsung Bioepis has not yet announced an aBLA filing for a Soliris® biosimilar in the U.S., its biosimilar candidate Epysqli" (eculizumab) was approved in the E.U. in May 2023.

Soliris® patents previously faced IPR challenges by Amgen in 2019 that resulted in settlements. To date there have not been any public announcements of aBLA filings for Soliris® biosimilars, nor have there been any BPCIA litigations related to a Soliris®biosimilar.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from